Next Article in Journal
Factors Associated with Adverse Reactions to BNT162b2 COVID-19 Vaccine in a Cohort of 3969 Hospital Workers
Next Article in Special Issue
Development of an Oral Salmonella-Based Vaccine Platform against SARS-CoV-2
Previous Article in Journal
The Signal Peptide and Chaperone UNC93B1 Both Influence TLR8 Ectodomain Intracellular Endosomal Localization
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 10
Issue 1
10.3390/vaccines10010013
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination: A Case Report

by
Giulia Costanzo
*,
Andrea Giovanni Ledda
,
Alessandra Ghisu
,
Matteo Vacca
,
Davide Firinu
and
Stefano Del Giacco
Department of Medical Sciences and Public Health, University of Cagliari, 09131 Cagliari, Italy
*
Author to whom correspondence should be addressed.
Vaccines 2022, 10(1), 13; https://doi.org/10.3390/vaccines10010013
Submission received: 20 November 2021 / Revised: 18 December 2021 / Accepted: 20 December 2021 / Published: 23 December 2021
(This article belongs to the Special Issue New Insights into Current and Future Vaccines against SARS-CoV-2 Variants of Concern and Interest)
Browse Figure
Review Reports Versions Notes

Abstract

Background: We here describe the case of a 71-year-old Caucasian woman previously diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA) that had been treated with Mepolizumab, an anti-IL5 monoclonal antibody, since 2019 with a good clinical response. Methods: She had a mild COVID-19 in December 2020 and she tested negative for SARS-CoV-2 infection in only late January 2021. In April 2021 she received the first dose of mRNA BNT162b2 vaccine. Ten days later she developed myalgia, dyspnea and numbness of the limbs due to a relapse of EGPA that occurred during Mepolizumab treatment.
Keywords: EGPA; COVID-19; vaccine; mRNA BNT162b2 vaccine; relapse EGPA; COVID-19; vaccine; mRNA BNT162b2 vaccine; relapse

Share and Cite

MDPI and ACS Style

Costanzo, G.; Ledda, A.G.; Ghisu, A.; Vacca, M.; Firinu, D.; Del Giacco, S. Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination: A Case Report. Vaccines 2022, 10, 13. https://doi.org/10.3390/vaccines10010013

AMA Style

Costanzo G, Ledda AG, Ghisu A, Vacca M, Firinu D, Del Giacco S. Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination: A Case Report. Vaccines. 2022; 10(1):13. https://doi.org/10.3390/vaccines10010013

Chicago/Turabian Style

Costanzo, Giulia, Andrea Giovanni Ledda, Alessandra Ghisu, Matteo Vacca, Davide Firinu, and Stefano Del Giacco. 2022. "Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination: A Case Report" Vaccines 10, no. 1: 13. https://doi.org/10.3390/vaccines10010013

APA Style

Costanzo, G., Ledda, A. G., Ghisu, A., Vacca, M., Firinu, D., & Del Giacco, S. (2022). Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination: A Case Report. Vaccines, 10(1), 13. https://doi.org/10.3390/vaccines10010013

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop